Northwire Canada EditionThursday, July 16, 2026
Sign inSubscribe
Northwire
⌕
HWY 0.370 +0.0% FCI 0.385 +1.3% GGAU 0.180 −5.3% KIRO 0.650 +1.6% LBNK 0.430 +0.0% BARU 0.040 +0.0% VCU 1.08 −5.3% NOBL 0.100 +0.0% SHL 0.350 −1.4% MTS 0.130 +0.0% FYL 0.090 +0.0% NUAG 5.43 −0.4% CAM 0.330 −1.5% SYH 0.400 −1.2% LOT 0.040 +0.0% CPL 0.210 +10.5% HWY 0.370 +0.0% FCI 0.385 +1.3% GGAU 0.180 −5.3% KIRO 0.650 +1.6% LBNK 0.430 +0.0% BARU 0.040 +0.0% VCU 1.08 −5.3% NOBL 0.100 +0.0% SHL 0.350 −1.4% MTS 0.130 +0.0% FYL 0.090 +0.0% NUAG 5.43 −0.4% CAM 0.330 −1.5% SYH 0.400 −1.2% LOT 0.040 +0.0% CPL 0.210 +10.5%
Production / Operations

MedX Health 2025 YEAR REVIEW

By The Northwire Desk — AI Analysis Dec 15, 2025 · 06:00 MDX · 0.055 Medx Health Corp.
MDX · Price

Executive Summary

  • MedX Health Corp. provided a comprehensive 2025 operational review, highlighting $2 M CAD of platform and IP investments, new executive appointments (CEO, CTO, COO), and expansion of its DermSecure® image database to ~85,000 clinically reviewed skin images.
  • The Photobiomodulation division launched two new laser product lines—LumaVet for veterinary use and Oralase for dental applications—with expectations that Oralase will drive meaningful growth in 2026.
  • A commercial agreement with Health Partners Group is set to roll out phased deployments to employer groups beginning Q1 2026, positioning the company for broader market expansion.

Key Details

  • Capital Investment: Over CAD $2 million invested in technology development, IP portfolio enhancement, compliance upgrades, and operational infrastructure during fiscal 2025.
  • Executive Appointments (Q3 2025): • New Chief Executive Officer • First Chief Technology Officer (overseeing internal engineers and external dermatology, imaging, ML advisers) • Chief Operating Officer appointed after signing a commercial agreement with Health Partners Group in Q1 2025.
  • DermSecure® Platform: Image database expanded to approximately 85,000 clinically reviewed skin images, each annotated for blood, melanin, and collagen components; supports AI‑driven analysis and IP protection.
  • Commercial Agreement: Executed with Health Partners Group (Q1 2025); phased rollout to employer groups slated to commence Q1 2026.
  • Photobiomodulation Division Revenue: Generated modest but steadily increasing revenues throughout 2025 as product lines expanded and regulatory alignment progressed.
  • New Laser Products Launched (2025): • LumaVet – cold‑laser system for veterinary pain management and tissue healing. • Oralase – dental laser SKU targeting oral care and dental practices; projected to be a significant growth driver in 2026.
  • CRO & Beauty/Aesthetics Services: Served >26 Contract Research Organizations across multiple jurisdictions, including major global beauty brands; continued development of integrated imaging/IP tools for enhanced workflow and analysis.
  • Licensing Update (Q1 2025): Released from exclusive licensing arrangement with Procter & Gamble, enabling direct pursuit of new licensing and commercial opportunities in skin health, aesthetics, and beauty markets.

Notable Quotes

“The initiatives undertaken throughout 2025 have positioned MedX to accelerate commercial activities across our core markets in 2026,” – John Gevisser, CEO, MedX Health Corp.

Read the original news release →

More from Medx Health Corp.

Jun 25, 2026 · 23:52

MedX Health Launches SkinSecure SaaS to Target CRO Market, But Liquidity Crisis and Going Concern Risks Dominate

Other May 15, 2026 · 19:40

MedX Secures Runway with Debt Refinancing Amidst Dilution Concerns and Modest Cash Injection

Financings Mar 16, 2026 · 07:00

MedX Announces Application for Extension of Non-Brokered Private Placement

Financings Feb 27, 2026 · 11:44

MedX Health closes $2.7-million private placement

Financings Feb 27, 2026 · 07:00

MedX Announces $2,700,000 Initial Closing of Non-Brokered Private Placement of Series IV Convertible Loan Notes

Financings Feb 02, 2026 · 21:05

MedX Health arranges $5-million note financing

Financings